Free tool
FAERS Monitor: Kisqali
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209092 or its brand name (Kisqali, Ribociclib Succinate). Reports on generic versions are filed under their own applications.
Reports
32,716
Serious
27,086
83% of reports
Hospitalization
7,508
Death reported
4,684
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- neutropenia4,342
- fatigue3,986
- nausea3,932
- malignant neoplasm progression2,842
- death2,554
- vomiting2,210
- diarrhoea2,125
- white blood cell count decreased2,076
- pain1,940
- metastases to bone1,825
- asthenia1,680
- breast cancer metastatic1,678
- malaise1,670
- dyspnoea1,652
- anaemia1,557
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 3 |
| 2016 | 3 |
| 2017 | 507 |
| 2018 | 1,211 |
| 2019 | 2,156 |
| 2020 | 3,064 |
| 2021 | 3,676 |
| 2022 | 4,013 |
| 2023 | 5,960 |
| 2024 | 3,887 |
| 2025 | 4,574 |
| 2026 | 3,662 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,021,443 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| breast cancer metastaticSignal | 1,678 | 118.9 | 113.0 | 165,556 |
| metastases to boneSignal | 1,825 | 80.3 | 76.6 | 127,058 |
| neutropeniaSignal | 4,342 | 21.2 | 20.6 | 81,301 |
| malignant neoplasm progressionSignal | 2,842 | 18.3 | 17.7 | 45,455 |
| white blood cell count decreasedSignal | 2,076 | 12.5 | 12.0 | 21,712 |
| anaemiaSignal | 1,557 | 5.3 | 5.0 | 5,407 |
| fatigueSignal | 3,986 | 3.3 | 3.2 | 6,611 |
| nauseaSignal | 3,932 | 3.2 | 3.1 | 6,165 |
| vomitingSignal | 2,210 | 3.0 | 2.9 | 3,061 |
| astheniaSignal | 1,680 | 2.9 | 2.7 | 2,089 |
| malaiseSignal | 1,670 | 2.5 | 2.3 | 1,462 |
| diarrhoeaSignal | 2,125 | 2.1 | 2.0 | 1,292 |
| painSignal | 1,940 | 2.0 | 1.9 | 1,046 |
| death | 2,554 | 1.9 | 1.8 | 1,147 |
| dyspnoea | 1,652 | 1.9 | 1.8 | 695 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.